Original paper
Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure
Abstract
Over the last decade, treatment for heart failure with reduced ejection fraction (HFrEF) has advanced, with the incremental addition of novel evidence-based medical therapies. The landmark PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study showed that the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan was superior to enalapril in reducing risk...
Paper Details
Title
Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure
Published Date
Jun 4, 2021
Journal
Volume
107
Issue
17
Pages
1364 - 1366